Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

NCT05614115 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

End-stage Kidney Disease
Kidney Disease, Chronic
Dialysis
Diabetic
Non-diabetic
Kidney Dysfunction
Kidney Failure
Hemodialysis

Interventions

DRUG: Empagliflozin
OTHER: Placebo

Sponsor

University of Utah

Collaborators

[object Object]